Affordable Access

Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.

Authors
Type
Published Article
Journal
European Journal of Clinical Pharmacology
0031-6970
Publisher
Springer-Verlag
Publication Date
Volume
27
Issue
5
Pages
529–534
Identifiers
PMID: 6151506
Source
Medline

Abstract

The efficacy of once-daily bopindolol, a nonselective beta-adrenoceptor blocking agent with partial agonist activity, and of pindolol and atenolol in the treatment of essential hypertension has been compared. 369 patients were investigated in a double-blind parallel-group study. The treatment period was 10 weeks. Blood pressure normalisation (diastolic BP equal to or less than 90 mmHg) was to be achieved by a stepwise increase in the dose of the test drugs, and, if required, by addition of a diuretic. Normalisation of blood pressure was achieved in 71 to 76% of the subjects, with no significant differences between bopindolol, pindolol, and atenolol. Special attention was given to evaluation of side effects by using two methods for registration of all adverse events during the study. A low incidence of drug-induced side effects was observed, with no significant difference between bopindolol, pindolol, and atenolol. There was no evidence of unsuspected adverse reactions due to bopindolol.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F